Comparative Pharmacology
Head-to-head clinical analysis: DEPO TESTOSTERONE versus TESTRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO TESTOSTERONE versus TESTRED.
DEPO-TESTOSTERONE vs TESTRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone binds to androgen receptors, activating gene transcription that promotes development of male secondary sexual characteristics, anabolic effects, and erythropoiesis.
Testosterone is an androgen receptor agonist, promoting development of male secondary sexual characteristics and anabolic effects.
50-400 mg IM every 2-4 weeks
Testosterone enanthate 200 mg intramuscularly every 2 weeks.
None Documented
None Documented
The terminal elimination half-life of testosterone cypionate after intramuscular injection is approximately 8 days, allowing for dosing every 2-4 weeks.
Terminal elimination half-life for testosterone is 2-4 hours; testosterone enanthate has a half-life of 4-5 days due to slow release from the oily depot. Clinical context: shorter half-life requires more frequent dosing for stable serum levels.
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (90%) and in feces via bile (10%).
Approximately 90% of administered testosterone is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites (androsterone, etiocholanolone). About 6% is excreted in feces via bile. Unchanged testosterone excretion is negligible (<1%).
Category D/X
Category C
Androgen
Androgen